The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004

Abstract

Background: National incidence rates for lobular and ductal breast cancers have not been available previously. Evidence suggests that the increased risk of breast cancer associated with combined hormone replacement therapy use is higher for invasive lobular cancers (ILC) than for invasive ductal cancers (IDC). This study provides U.S. incidence rates for these histologic types for both in situ and invasive cancers and assesses changes in the incidence of these cancers over time. Methods: Data for this study included incident ductal and lobular breast cancer cases diagnosed from 1999 through 2004 in central cancer registries in 44 states and the District of Columbia from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program. We estimated incidence per 100,000 women by 10-year age groups, race, and eth-

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years

“…Lobular cancers have also been postulated to be particularly sensitive to hormonal stimulation. While a few investigators have reported larger recent decreases in incidence for lobular cancers than for ductal cancers [14,20], we found no evidence of a different incidence pattern for the small subgroup of lobular carcinomas available for analyses in the present study.…”

Breast Cancer Thirty Years Later: A Comparative Study between A 1983-1984 AND A 2012-2013 Cohorts of Argentine Women

“…This increase is also observed globally [61]; our data in relation to the increase of the non-infiltrating forms are very coincident with those reported in a US series that reported a fivefold increment of the frequency of non-infiltrative forms, mainly ductal, in the past 25 years [62,63]. Pure DCIS accounts for 15 to 20% of breast cancers compared with only 5% of cases before the advent of breast cancer screening [64,65].…”

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

“…With advances in breast cancer screening and mammography, cancer registries now indicate that DCIS represents close to 20% of the breast carcinomas diagnosed in the United States (38,39). DCIS itself is noninvasive, but cancer recurring after DCIS treatment is often invasive.…”